Brandes Investment Partners 13F: Adds $13M to CVS Stake
Brandes Investment Partners grew its CVS Health position by 124,459 shares during the period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brandes Investment Partners added 124,459 shares to its stake in CVS Health Corporation ($CVS), a 6.74% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 1,969,801 shares worth $203.82 million at the end of the quarter.
Since the filing, $CVS is down 2.7% after 1 week, up 5.0% after 1 month and down 3.1% to date (from the $95.30 close on May 15, 2026).
Find the original: Brandes Investment Partners 13F filings on SEC EDGAR
CVS
CVS Health Corporation
Key Points
- Brandes Investment Partners boosted its CVS Health Corporation stake by 6.7%, adding 124,459 shares to finish the period with 1,969,801 shares worth approximately $203.8 million.
- CVS Health Corporation shares trade near $103.47, with a P/E ratio of 24.4 and a forward P/E of 10.8.
- Wall Street analysts hold a strong buy consensus on CVS Health with a mean price target of $115.48 across 25 opinions.
Get $CVS trade alerts by text
We text you when insiders, Congress or big funds trade $CVS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CVS Health Corporation alert may contain errors. Disclosures
Brandes Investment Partners Increases CVS Health Holdings
Brandes Investment Partners increased its position in CVS Health Corporation (NYSE: CVS) during the period, according to a Form 13F filed with the U.S. Securities and Exchange Commission. The filing reflects holdings as of the reporting period and may not represent the investor's current position.
Position Details for CVS Health
The fund added 124,459 shares of CVS Health Corporation, resulting in a 6.7% increase to its holdings. Brandes Investment Partners previously held 1,845,342 shares and closed the period with 1,969,801 shares. The reported value of the stake reached approximately $203.8 million based on the filing data.
CVS Health Stock Performance
CVS Health Corporation shares traded at $103.47. The stock has a 52-week low of $69.51 and a 52-week high of $110.68. Its 50-day moving average sits at $91.80, while its 200-day moving average stands at $88.12. The company carries a market capitalization of $118.41 billion, a P/E ratio of 24.36, and a forward P/E of 10.85.
Recent Earnings Overview
For its financial results, CVS Health Corporation reported $412.65 billion in revenue with a revenue growth rate of 7.1%. The company posted earnings per share of $3.80, alongside a net margin of 1.18% and a return on equity of 6.21%. The next earnings release is scheduled for November 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
11 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 15.8%. Revenue beat estimates by 4.6%.
-
Profit surprise
EBITDA beat by 15 percent. Operating income beat by 4 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
11 target raises.
-
Earnings quality
Operating margin up 1.1 points. Positive free cash flow.
Earnings Call Summary
CVS delivered a strong first quarter with $100.4 billion in revenue, up 6 percent year over year, and earnings per share of $2.57, beating consensus by 36 cents. The Aetna health insurance business showed major improvement with operating income up 1 billion dollars year over year and a better medical benefit ratio. Pharmacy sales grew 3 percent at existing stores driven by strong prescription volume increases. Management is focused on affordability, reducing friction in the health system, and launching a new consumer app called Health100 powered by artificial intelligence.
Guidance CVS raised full year earnings guidance to $7.30 to $7.50 per share, up from $7.00 to $7.20. They expect at least $405 billion in revenue for the year. Operating cash flow guidance improved to at least $9.5 billion.
Good report. The company beat and showed some forward improvement, with a few meaningful caveats.
Dividend Metrics
CVS Health Corporation pays an annual dividend yield of 2.87% with a dividend payout ratio of 70.0%.
Analysts Set New Price Targets
Wall Street firms continue to update their views on CVS Health Corporation. On October 12, 2026, Leerink Partners maintained its Outperform rating and lowered its price target from $119.00 to $112.00. Earlier, on September 3, 2026, UBS maintained a Buy rating while lowering its target from $126.00 to $118.00. Argus Research maintained a Buy rating on August 19, 2026, raising its target from $104.00 to $114.00. JP Morgan kept an Overweight rating on August 12, 2026, lifting its target from $111.00 to $118.00. Additional recent updates include UBS maintaining a Buy rating at a $126.00 target on August 6, 2026, Evercore ISI Group maintaining an Outperform rating with a reduced $125.00 target on August 6, 2026, and Barclays maintaining an Overweight rating with a target moving from $106.00 to $108.00 on August 6, 2026. Across 25 analyst opinions, the stock carries a strong_buy recommendation key and a target mean price of $115.48, with targets ranging from a low of $103.00 to a high of $145.00.
About CVS Health Corporation
CVS Health Corporation operates as a healthcare company in the United States, offering health insurance products, pharmacy benefit management solutions, and retail pharmacy services. The company connects health plan members, employers, and government entities with medical plans, prescription drug coverage, and consumer wellness products.
What to Watch at CVS Health Corporation
Investors tracking Brandes Investment Partners will look to subsequent 13F filings to see if the firm adjusts its healthcare allocations further. Market participants should also monitor CVS Health Corporation's upcoming earnings report on November 4, 2026, for updates on its operational segments and financial targets.
Related Filing Alerts
Source: Brandes Investment Partners's 13F filing on $CVS (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Brandes Investment Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts